Novel selective PDE4 inhibitors. 3. In vivo antiinflammatory activity of a new series of N-substituted cis-tetra- and cis-hexahydrophthalazinones

Journal of Medicinal Chemistry

Volumn 45, Issue 12, 2002, Pages 2520-2525

  Van der Mey, Margaretha ^a,b   Boss, Hildegard ^c   Hatzelmann, Armin ^c   Van der Laan, Ivonne J ^b   Sterk, Geert J ^b   Timmerman, Hendrik ^a  

^a VU UNIVERSITY AMSTERDAM   (Netherlands)

^b Byk Nederland   (Netherlands)

^c Byk Gulden ^*  (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

4A,5,6,7,8,8A HEXAHYDROPHTHALAZINONE DERIVATIVE; 4A,5,8,8A TETRAHYDRO 2H PHTHALAZIN 1 ONE DERIVATIVE; ANTIINFLAMMATORY AGENT; FORMYLMETHIONYLLEUCYLPHENYLALANINE; N ADAMANTANYLTETRAHYDROPHTHALAZINONE DERIVATIVE; N CYCLOHEPTYLTETRAHYDROPHTHALAZINONE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; PHTHALAZINE DERIVATIVE; REACTIVE OXYGEN METABOLITE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CIS ISOMER; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG ACTIVITY; DRUG POTENCY; DRUG RESEARCH; DRUG SELECTIVITY; DRUG SPECIFICITY; DRUG SYNTHESIS; FEMALE; HUMAN; HUMAN CELL; IC 50; INHIBITION KINETICS; MOUSE; NONHUMAN; OXIDATIVE STRESS; STRUCTURE ACTIVITY RELATION;

3',5'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASE; ADAMANTANE; ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CHEMILUMINESCENT MEASUREMENTS; CYCLOHEPTANES; EDEMA; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKOCYTES, MONONUCLEAR; LIPOPOLYSACCHARIDES; MICE; PHTHALAZINES; REACTIVE OXYGEN SPECIES; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037030655     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0110340     Document Type: Article

References (24)

1. Interaction of PDE4 inhibitors with enzymes and cell functions
2. Emerging opportunities in the treatment of asthma and allergy
3. Novel phosphodiesterase inhibitors for the therapy of asthma
4. Novel selective PDE4 inhibitors. 1. Synthesis, structure-activity relationships, and molecular modeling of 4-(3,4-dimethoxyphenyl)-2H-phthalazin-1-ones and analogues
5. Novel selective PDE4 inhibitors. 2. Synthesis and structure-activity relationships of 4-aryl-substituted cis-tetra- and cis-hexa-hydrophthalazinones
6. The specific type III and IV phosphodiesterase inhibitor zardaverine suppresses formation of tumour necrosis factor by macrophages
7. Influence of selective phosphodiesterase inhibitors on human neutrophil functions and levels of cAMP and Ca
8. Phosphodiesterase inhibitors: New opportunities for treatment of asthma
9. A high-yielding synthesis of monoalkylhydrazines
10. Inhibition of cyclic adenosine3′,5′-monophosphate phosphodiesterase from vascular smooth muscle by rolipram analogues
11. 1,4-Cyclohexanecarboxylates: Potent and selective inhibitors of phosphodiesterase 4 for the treatment of asthma
12. The design and synthesis of CDP 840, an orally active PDE IV inhibitor for asthma
13. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis
14. Cytokines as mediators of chronic asthma
15. Pharmacological evidence for tumor necrosis factor as a mediator of allergic inflammation in the airways
16. Phosphodiesterase isozymes-molecular targets for novel antiasthma agents
17. The effects of antiinflammatory and antiallergic drugs on cytokine release after stimulation of human whole blood by lipopolysaccharide and zymosan A
18. Seeing the wood for the trees: The forgotten role of neutrophils in rheumatoid arthritis
19. The neutrophil respiratory burst mechanism
20. Analysis of PDE isoenzyme profiles in cells and tissues by pharmacological methods
21. Differential inhibition of human neutrophil function. Role of cAMP-specific, cGMP-insensitive phosphodiesterase
22. Allen inhibitors: The use of molecular cloning in the design and development of novel drugs
23. Effect of selective phosphodiesterase type IV inhibitor, rolipram, on fluid and cellular phases of inflammatory response
24. Regulation of 5-lipoxygenase activity by the glutathione status in human polymorphonuclear leukocytes